erlotinib or gefitinib (AstraZeneca)

\"erlotinib or gefitinib\" is not a single chemical entity; it denotes an alternative-treatment choice between **erlotinib** and **gefitinib**, two distinct oral, first-generation small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Both reversibly inhibit the ATP-binding kinase domain of EGFR, suppressing downstream proliferative and survival signaling in EGFR-driven tumors. In the Anhui Medical University Phase 2 study NCT01965275, patients with advanced non-small cell lung cancer progressing after standard-dose EGFR-TKI therapy received high-dose pulsatile treatment with either erlotinib or gefitinib rather than a co-formulated or concurrently administered erlotinib-gefitinib product. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01965275))

Brand names

TarcevaIressa